Neoleukin Therapeutics Inc

Change company Symbol lookup

Select an option...

NLTX Neoleukin Therapeutics Inc

RNXT RenovoRx Inc

BNTX BioNTech SE

ARTW Art's Way Manufacturing Co Inc

ARIZU Arisz Acquisition Corp

OSH Oak Street Health Inc

LESL Leslie's Inc

AAPL Apple Inc

BYM BlackRock Municipal Income Quality Trust

DLA Delta Apparel Inc

Go

Neoleukin Therapeutics, Inc. is a biopharmaceutical company. The Company is engaged in providing immunotherapies for cancer, inflammation, and autoimmunity using de novo protein design technology. The Company's lead product candidate, NL-201, is an interleukin-2 (IL-2)/ interleukin-15 (IL-15) immunotherapy designed to eliminate binding to the alpha subunit of the IL-2 receptor (also known as CD25) while enhancing binding to the beta and gamma subunits. NL-201 is designed to mimic the therapeutic activity of the cytokines IL-2 and IL-15 for the treatment of various types of cancer, including renal cell carcinoma (RCC), melanoma and hematological malignancies. Its Neoleukin platform uses a set of advanced computational algorithms and methods to design functional de novo proteins. NL-201 holds promise in combination with cell therapy to expand and maintain populations of transplanted CAR-T and natural killer (NK) cells.